ORGS — Orgenesis Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.56m
- $17.16m
- $1.04m
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules
Brief: Orgenesis Provides Business Update For The First Quarter Of 2024
Brief: Orgenesis Inc Files For Mixed Shelf Of Up To $100 Million
Brief: Orgenesis Board Says Financial Statements For Qtrs Ended March 31, 2023, June 30, 2023, Sept 30, 2023, To No Longer Be Relied Upon
Brief: Orgenesis Provides Year End Business Update
Brief: Orgenesis Says There Is Substantial Doubt About Its Ability To Continue As A Going Concern
Brief: Orgenesis Acquires Control Of Octomera
Brief: Orgenesis- Elliot Maltz,CFO, Treasurer And Secretary Of Co, Resigned From All Positions He Held With Co
Brief: Orgenesis Announces Pricing of $1.1 Mln Registered Direct Offering
Brief: Octomera and UC Davis Expand Partnership Through CIRM Grant Funding
Brief: Orgenesis Announces Withdrawal Of Proposed Public Offering
Brief: Orgenesis Says Got Notice Of Delisting Or Failure To Satisfy A Listing Rule From Nasdaq
Orgenesis Inc reports results for the quarter ended in June - Earnings Summary
Orgenesis Inc expected to post earnings of 6 cents a share - Earnings Preview
Brief: Orgenesis Inc. Q2 revenue USD 7 million
Orgenesis names new finance chief